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Using an adenoviral system as a delivery mediator of therapeutic gene, we investigated the therapeutic effects of the use
of combined MDR1 shRNA and human NIS (hNIS) radioiodine gene therapy in a mouse colon xenograft model. In vitro uptake of
Tc-99m sestamibi was increased approximately two-fold in cells infected with an adenovirus vector that expressed MDR1 shRNA
(Ad-shMDR1) and I-125 uptake was 25-fold higher in cells infected with an adenovirus vector that expressed human NIS (Ad-hNIS)
as compared with control cells. As compared with doxorubicin or I-131 treatment alone, the combination of doxorubicin and I-131
resulted in enhanced cytotoxicity for both Ad-shMDR1- and Ad-hNIS-infected cells, but not for control cells. In vivo uptake of Tc-
99m sestamibi and Tc-99m pertechnetate was twofold and 10-fold higher for Ad-shMDR1 and Ad-hNIS-infected tumors as
compared with tumors infected with a control adenovirus construct that expressed b-galactrosidase (Ad-LacZ), respectively. In mice
treated with either doxorubicin or I-131 alone, there was a slight delay in tumor growth as compared to mice treated with Ad-LacZ.
However, combination therapy with doxorubicin and I-131 induced further significant inhibition of tumor growth as compared with
mice treated with Ad-LacZ. We have shown successful therapeutic efficacy of combined MDR shRNA and hNIS radioiodine gene
therapy using an adenoviral vector system in a mouse colon cancer model. Adenovirus-mediated cancer gene therapy using MDR1
shRNA and hNIS would be a useful tool for the treatment of cancer cells expressing multi-drug resistant genes.
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Introduction
The human sodium/iodide symporter (NIS) protein is
an active iodide transporter.
1 As the transfer of the NIS
gene and the subsequent functional expression of NIS
protein induce cancer cells to accumulate therapeutic
radionuclides (I-131 and Re-188) from plasma, NIS gene
transfer represents a possible type of radionuclide gene
therapy. Several investigators have reported that human
sodium/iodide symporter (hNIS) mediated radionuclide
gene therapy would offer a potential means of cancer
therapy.
2–6
Multidrug resistance (MDR) is the most common
impediment to successful chemotherapy for various
cancers. Classic MDR is characterized by cross resistance
to antineoplastic drugs and is caused by overexpression of
the MDR1 gene that encodes P-glycoprotein (Pgp), a
member of the ATP-binding cassette transporter super-
family.
7 Most efforts to reverse MDR during the past
decades have focused on the use of compounds that
modulate Pgp activity. However, the efficiency of these
drugs was difficult to assess because of inherent adverse
side effects such as hypotension and heart failure.
Moreover, tumor cells can acquire resistance to the
applied chemosensitizer’s so-called tertiary resistance.
Experimental therapeutic strategies to reverse MDR
are under investigation. These strategies included gene
therapeutic approaches with the use of antisense oligo-
nucleotides, ribozymes or DNAzymes and, most recently,
the application of RNA interference (RNAi) techno-
logy.
8,9 RNAi is a conserved cellular mechanism where
double-stranded RNA silences the corresponding homo-
logous gene.
8,9 Double-stranded small-interfering RNA
(siRNA) molecules with a length of 19–25 nucleotides can
direct degradation of eukaryotic mRNAs in a sequence-
specific manner. Transient RNAi can be attained by
application of siRNAs, whereas stable RNAi-mediated
gene silencing can be achieved by transfection of
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encoding expression cassettes that are localized on
plasmid or viral vectors.
Previously, we have reported on the increased thera-
peutic effects of combination MDR1, shRNA and hNIS
radioiodine gene therapy in human cancer cells in vitro
using stable transfectants that express MDR1 shRNA for
the MDR1 gene and human NIS (hNIS) gene.
10 Although
the in vitro study showed a therapeutic effect in a human
colon cancer model, the application of our findings in a
clinical setting is not straightforward. We have attempted
to identity a new method to treat drug-resistance cancer
effectively in vivo, which mimics the clinical situation.
Among various therapeutic strategies, we have focused on
the use of adenovirus-mediated therapeutic gene delivery
in an in vivo cancer model. An adenoviral vector is the
major delivery system commonly used for gene therapy in
vivo.
11,12 The use of an adenoviral vector system has been
reported to have several beneficial features as compared
with other viral vector systems, such as efficient transfec-
tion in various cells including both quiescent and dividing
cells, and high level expression of the gene of interest by the
use of a cytomegalovirus promoter during the short term.
In this study, we have attempted to show whether
adenovirus-mediated MDR1 shRNA plus hNIS gene
transfer in a human colon cancer model would be
potentially visualized by the use of nuclear imaging and
subsequently generate strong therapeutic effects in vivo.
Materials and methods
Cells and animals
The human colon cancer cell line HCT-15 was maintained
in RPMI 1640 containing 20% fetal bovine serum
(Hyclone, Logan, UT) and 50unitsml
–1 streptomycin/
penicillin (GibcoBRL, Grand Island, NY) at 371Ci na
humidified atmosphere containing 5% CO2. Specific
pathogen-free 6-week-old male BALB/c nude mice were
obtained from SLC (Hamamatsu, Japan).
Construction of an adenovirus vector expressing MDR1
shRNA or hNIS gene
The shRNA sequence targeting the human MDR1
gene corresponded to the coding region at positions 79–99:
50-AAGGAAAAGAAACCAACTGTC-30) (GenBank ac-
cession number NM_000927). shRNA duplexes with
the following sense and antisense sequences were
used: 50-TCGAGCGACAGTTGGTTTCTTTTCCGCG
GCCGCAGGAAAAGAAACCAACTGTCTTTTTTCC
AAA (sense) and 50-AGCTTTTGGAAAAAAGACAGT
TGGTTTCTTTTCCTGCGGCCGCGGAAAAGAAAC
CAACTGTCGC (antisense). All of the shRNA duplexes
were synthesized by Bioneer (Daejon, Korea) and were
annealed. shRNA for targeted MDR1 mRNA was cloned
into the XhoI and HindIII sites of the pRNAT H1-1
vector (GenScript, Piscataway, NJ) using an adenoviral
vector system.
Ad-shMDR1 is a recombinant adenovirus expressing
the human MDR1 shRNA and the green fluorescent
protein gene under the control of the immediate early
promoter of cytomegalovirus. The shuttle pRNAT H1-1
vector was homologously recombined with pAdEasy-1
(the E1–E3 early region has been deleted) vector into
electro-competent BJ5183 bacteria and was selected on
kanamycin LB plates. The complete Ad-shMDR1 virus
was recovered by transfection of 10mgP ac I digested
DNA into human embryonic kidney (HEK 293) cells by a
lipofectamine-based procedure. Adenoviruses expressing
the human NIS gene were kindly provided by Dr KH Lee.
Recombinant adenoviruses encoding b-galactosidase (Ad-
LacZ) were used as negative controls for the in vitro study.
All viral stocks were prepared from infected human
embryonic kidney cells (HEK 293) by the use of standard
procedures. After two-step purification on CsCl gradi-
ents, viral stocks were desalted by the use of G50 columns
(Pharmacia, Orsay, France) and were frozen at  701Ci n
PBS containing 10% glycerol. Viral titers were calculated
by determination of the TCID50 or with the use of the
adeno-X rapid titer kit (BD Bioscience, Palo Alto, CA).
Titers are expressed as either multiplicity of infection
(MOI) or as plaque forming units (PFU)/ml.
Western blotting
Cells were washed twice with PBS. Cells in cold PHI
buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, 5mM
Na2EDTA, 0.5% NP-40, 100mM phenylmethylsulphonyl
fluoride, 1mgml
–1 aprotinin, 1mgml
–1 leupeptin, 1mM
DTT) were scraped from dishes and left on ice for 30min
with occasional vortexing. The lysates were cleared by
centrifugation at 12000r.p.m. for 10min at 41C. Identical
amounts (40 and 80mg of protein) of cell lysates were
resolved by 8% SDS-PAGE (polyacrylamide gel electro-
phoreseis). Proteins were transferred to nitrocellulose
membranes in transfer buffer with or without methanol
and the membranes were incubated in blocking solution
consisting of 5% skim milk with TBST (10mM Tris-HCl
(pH 8.0), 150mM NaCl and 0.1% Tween 20) at
room temperature for 1h. The membranes were then
immunoblotted with monoclonal anti-Pgp antibody
C219 (170kDa; Calbiochem, La Jolla, CA), monoclonal
anti-NIS FP5A (90kDa; Lab Vision, Fremont, CA),
monoclonal anti-b-actin antibody (Sigma-Aldrich, St
Louis, MO) and monoclonal anti-a-tubulin antibody
(Sigma-Aldrich). Enzyme-linked chemiluminescence was
performed to measure absorbance according to the
manufacturer’s protocol (ECL; Amersham Pharmacia
Biotech, Piscataway, NJ). Expression of each protein was
verified by exposure to X-ray film.
In vitro Tc-99m sestamibi uptake
Tc-99m sestamibi (MIBI) (Cardiolite; Bristol-Myers
Squibb Medical Imaging, Columbus, OH) is a lipophilic
cationic radiopharmaceutical for myocardial and cancer
imaging with a gamma camera, and is believed to be
transported as a common transport substrate by
P-glycoportein (Pgp).
13 The decreased intracellular level
of substrate is because of enhanced efflux by membrane
transporters,
14 and reduced MIBI uptake in an MDR-
expressing tumor is related to Pgp.
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6 cells per well in 6-well
plates 1 day before viral infection. The Tc-99m sestamibi
uptake assay was performed at 48h after virus infection of
200 MOI of Ad-shMDR1 with or without 20 MOI of
Ad-hNIS. Cells were washed once with 2ml PBS and were
then initiated by the addition of 0.1ml PBS containing
370kBq of Tc-99m sestamibi per well. After incubation
for 30min at 371Ci n5 %C O 2, cells were washed two
times with cold PBS. The radioactivity incorporated in
cells was measured with a well gamma-counter (Packard
Canberra, Downers Grove, IL). The radioactivity incor-
porated in cells was normalized for total protein, which
was measured with a bicinchoninic acid protein assay
(Pierce, Rockford, IL). Uptake of Tc-99m sestamibi was
expressed as c.p.m. per mg protein.
I-125 uptake assay
Cells were plated at 2 10
5 cells per well in 24-well plates
and iodide uptake experiments were performed at 48h
after virus infection of 200 MOI of Ad-shMDR1 with or
without 20 MOI of Ad-hNIS. Cells were washed once
with 1ml HBSS and then the iodide uptake assay was
initiated by the addition of 0.5ml HBSS containing
3.7kBq carrier-free I-125 and/or 10mM sodium iodide
(specific activity, 740MBqmM1) per well. After incuba-
tion with I-125 for 30min at 371C, cells were washed two
times with cold HBSS. The radioactivity of cells was
quantified with a well gamma-counter (Packard Canberra).
The radioactivity of cells was normalized for total protein
and I-125 uptake was expressed as c.p.m.mg
–1 protein.
For the inhibition study, radioiodine uptake was mea-
sured after pretreatment with 50mM potassium perchlo-
rate for 1h and radioactivity incorporated in cells was
measured.
In vitro cytotoxicity of doxorubicin
At 1 day before viral infection, 2 10
4 cells were seeded
in 96-well plates and co-infected with both 20 MOI of
Ad-shMDR1 and 200 MOI of Ad-hNIS. Infected cells
were incubated at 371C in a humidified atmosphere
containing 5% CO2 for 48h in the presence of 0.01, 0.1, 1,
60, 250, 500 and 1000mM doxorubicin (Sigma Aldrich).
Two days after doxorubicin treatment, a 10ml cell count
solution (CCK-8; Dojindo, Tokyo, Japan) was added to
the culture medium of cells treated with doxorubicin and
plates were incubated at 371C for 4h. Absorbance was
measured at a wavelength of 450nm using a microplate
reader and cellular viability (%) was determined.
In vitro clonogenic assay
The clonogenic assay has been described previously.
4
Briefly, non-infected cells or cells co-infected with both
Ad-shMDR1 and Ad-hNIS were grown in a 75-cm
2 flask
and were incubated with either 5ml HBSS (control) or
HBSS containing 9.25 and 18.5MBq of I-131. At 7h after
incubation with I-131, cells were washed twice with cold
HBSS, trypsinized and counted. Treated cells were plated
in 6-well plates 1000 (1000 cells per well) and were
incubated with or without 1 or 10mM doxorubicin at 371C
for 1 week. Cells were then washed twice with PBS
and were stained with a crystal violet solution. Colonies
of more than 30 cells were counted and the results
are expressed as the percentage of surviving colonies
obtained after treatment with I-131 or doxorubicin or
I-131 plus doxorubicin as compared with cells treated
only with HBSS.
In vivo imaging of tumor-bearing mice
A total of 1 10
7 HCT-15 cells were challenged to both
thighs of nude mice. When the tumor volume reached
approximately 100mm
3, Ad-shMDR1 (2 10
9PFU) and
Ad-hNIS (1 10
9PFU) were co-injected into the mouse
tumors. Ad-LacZ was administered as a control. Each
virus was introduced to mice by multiple injections of
virus into each tumor.
Two days after viral infection, 18.5MBq Tc-99m
sestamibi or Tc-99m pertechnetate was injected into
tumor-bearing mice via the tail vein. At 60min after the
injection of the radiotracer, scintigraphic imaging was
acquired with the use of a multipurpose gamma camera
(Infinia, GE, Milwaukee, WI) equipped with a pinhole
collimator. An enhanced green fluorescent protein fluore-
scence image was obtained using OPtix (Advanced
Research Technologies, Montreal, Canada).
In vivo animal tumor therapy
A total of 1 10
7 cells HCT-15 cells were s.c injected into
both thighs of nude mice. When the diameter of tumors
were approximately X100mm
3 (approximately 10 days
after injection), cancer therapy was started. Mice were
subdivided into four groups for in vivo therapy (control
mice treated with PBS only, mice treated with doxorubicin,
mice treated with I-131 and mice given combination
treatment with doxorubicin and I-131). For I-131 therapy,
mice received a low-iodine diet with T4 supplementation in
drinking water for 2 weeks to maximize radioiodine uptake
in tumors and to reduce iodide uptake by the thyroid gland.
Ad-shMDR1 (2 10
9PFU) and Ad-hNIS (1 10
9PFU)
was co-injected into tumors in the left thigh (for mice that
underwent therapy). Ad-LacZ as a control was adminis-
tered into tumors in the right thigh (control mice). Two
days later, a single injection of either 55.5MBq I-131 or
0.5mgkg
–1 doxorubicin was i.p injected once per 3 days for
9 days. The tumor volume (length width height 0.52)
was measured at 3-day intervals for 21 days.
Histopathological analysis
Tumor masses were removed from mice and were preserved
in 10% formalin until required. All tumor masses were
embedded in paraffin, sectioned at 5mm and were stained
with hematoxylin and eosin (H&E staining).
For immunohistological analysis of Pgp and hNIS, the
paraffin sections were incubated for 1h with anti-Pgp
and anti-NIS antibodies at a 1:100 and 1:50 dilution,
respectively. Sections were then incubated for 30min with
a goat anti-rabbit secondary antibody conjugated to
peroxidase (Immunotech, Marseille, France).
For immunohistological analysis of b-galactosidase,
5mm cryosections were washed with 2ml PBS at
room temperature. A 5ml solution of cell fixative
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was added and the slides were then washed once with
PBS. Slides were incubated with X-gal staining solution
for 14h at 371C in the dark and were examined under a
light microscope (magnification,  200).
Statistical analysis
Data are presented as the mean±s.d. Inter-group
differences were assayed using the two-tailed Student’s
t-test. P-values of o0.05 were considered as statistically
significant.
Results
Increased uptake of Tc-99m sestamibi and I-125 in
Ad-shMDR1/Ad-hNIS-infected HCT-15 cells
Increased human NIS protein expression was observed in
Ad-hNIS-infected cells, and decreased P-glycoprotein
expression was found in Ad-shMDR1-infected cells as
determined by western blotting. Also, it was shown that
the I-125 uptake was increased up to 25-fold higher in
Ad-hNIS-infected cells as compared with non-infected cells,
and specifically inhibited in the presence of potassium
perchlorate (known inhibitors of hNIS function). A
reduction of MDR1 gene expression was determined by
RT-PCR analysis in Ad-shMDR1-infected cancer cells, as
reported previously.
15
The uptake of Tc-99m sestamibi was significantly
increased in Ad-shMDR1 or in both Ad-shMDR1 and
Ad-hNIS-infected HCT-15 cells, but not in parental cells
(Figure 1a, Po0.05) and uptake was approximately two-
fold higher for the use of both constructs as compared
with that of the parental cells. Concurrently, I-125 uptake
was 26-fold and 22-fold higher in Ad-hNIS or
Ad-shMDR1/Ad-hNIS-infected HCT-15 cells, respec-
tively, as compared with the parental cells (Figure 1b,
Po0.05). I-125 uptake in Ad-hNIS-infected cells was
slightly higher as compared with uptake for both
Ad-hNIS and Ad-shMDR1 infected cells, but did not
reach statistical significance. I-125 uptake in hNIS-
expressing cells was almost completely inhibited by
treatment with perchlorate, a competitive NIS inhibitor.
In vitro treatment with doxorubicin and I-131
The survival rates of cells in the presence of 1 and 60mM
doxorubicin were significantly lower for Ad-shMDR1 or
Ad-shMDR1/Ad-hNIS infected cells as compared with
non-infected-parental cells (Figure 2a, Po0.05). In vitro
clonogenic assays showed that viability was reduced in
Ad-hNIS-infected HCT-15 cells in a dose-dependent
manner, but not in parental cells; treatment with
37MBq I-131 markedly decreased viability (Figure 2b,
Po0.05). Subsequently, combination treatment with
I-131 and doxorubicin generated more enhanced cellular
cytotoxic effects in Ad-shMDR1/Ad-hNIS-infected HCT-15
cells as compared with that of control cells (Figure 3).
Particularly, the highest cellular cytotoxicity was observed
in cells treated with the combination of 18.5MBq I-131
and 10mM doxorubicin as compared with control cells
(control cells and both 18.5MBq I-131 and 10mM
doxorubicin-treated cells, 19 and 100%, respectively).
In vivo imaging of tumors treated with both Ad-shMDR1
and Ad-hNIS
Scintigraphic imaging revealed increased uptake of
Tc-99m sestamibi in Ad-shMDR1/Ad-hNIS-infected
tumors, but not in Ad-LacZ-infected tumors (Figure 4a). In
addition, higher uptake of Tc-99m pertechnetate was
Figure 1 Functional uptake of Tc-99m sestamibi and I-125 in
Ad-shMDR1 or Ad-hNIS-infected HCT-15 cells. HCT-15 cells were
infected with Ad-shMDR1 (200 MOI) or Ad-shMDR1 (200 MOI) plus
Ad-hNIS (20 MOI) for 48h and were incubated with 370kBq Tc-99m
sestamibi for 30min (a). I-125 uptake was performed in transfected
HCT15 cells with Ad-hNIS (20 MOI) or Ad-hNIS (20 MOI) plus
Ad-shMDR1 (100 MOI). I-125 uptake was then initiated for 30min by
the addition of 0.5ml HBSS containing 3.7kBq of I-125 per well and
was blocked in the presence of potassium perchlorate, a known
inhibitor of NIS function (b). Results are expressed as the mean of
c.p.m. per protein concentration. The data shown are the means of
experiments performed in triplicate. Bars represent means±s.d.;
NS, not significant; *statistically significant.
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tumors as compared with Ad-LacZ-infected HCT-15
tumors by the use of a gamma camera (Figure 4b).
Physiological uptake of Tc-99m was seen in the thyroid
and stomach expressing hNIS. Fluorescence imaging
showed an enhanced green fluorescent protein signal
in Ad-shMDR1/Ad-hNIS-infected tumors, but not in
Ad-LacZ-infected tumors (Figure 4c).
Immunohistological analysis of Ad-shMDR1/Ad-hNIS or
Ad-LacZ-infected tumors
Immunohistological staining using anti-P-glycoprotein
and anti-hNIS revealed that P-glycoprotein expression
was reduced in Ad-shMDR1/Ad-hNIS-infected tumors,
but not in Ad-LacZ-infected tumors (Figures 5b and e),
whereas increased expression of hNIS protein was only
detected in Ad-shMDR1/Ad-hNIS-infected tumors, but
not in Ad-LacZ-infected tumors (Figures 5a and d). LacZ
(E. coli b-galactosidase) protein expression was detected in
Ad-LacZ-infected tumors, but not in Ad-shMDR1/Ad-
hNIS-infected tumors by the use of X-gal (Figures 5c and f).
In vivo therapy with doxorubicin, I-131 and
doxorubicin plus I-131
Figure 6a shows the scheme of in vivo tumor treatment to
evaluate of therapeutic effects of combination therapy. As
shown in Figure 6b, weak inhibition of tumor growth was
observed in a tumor model infected with Ad-shMDR1 or
Ad-hNIS, followed with either I-131 or doxorubicin
treatment alone for 21 days post-tumor challenge. For
mice treated either with I-131 or doxorubicin, 248±21
and 227±21% of the initial tumor volume was deter-
mined, respectively. However, the tumor volume rapidly
increased and reached to 380±45% of the initial tumor
volume for mice treated with PBS (PBS versus doxoru-
bicin or I-131-treated mice, Po0.05, respectively).
Combination therapy using doxorubicin plus I-131
generated significant tumor growth inhibition in tumor-
bearing mice injected with virus mixture (Ad-shMDR1
and Ad-hNIS), and the tumor volume increased only
75±23% of the initial tumor volume at 21 days (mice
treated with PBS, I-131 and doxorubicin versus mice
treated with doxorubicin plus I-131, Po0.05). However,
no therapeutic effects with either I-131 and doxorubicin
treatment alone or I-131 plus doxorubicin were observed
in the Ad-LacZ-infected tumor model (the tumor volume
increases for the PBS, doxorubicin, I-131 and doxorubicin
Figure 2 Cytotoxic effects of doxorubicin or I-131 in Ad-shMDR1
and Ad-hNIS-infected cancer cells. HCT-15 cells (infected with
HBSS, 20 MOI Ad-hNIS, 200 MOI Ad-shMDR1 and both 200 MOI
Ad-shMDR1 and 20 MOI Ad-hNIS) were incubated in the presence of
0, 0.01, 0.1, 1, 60, 250, 500 and 1000mM doxorubicin for 48h at 371C
(a). HC-T15 cells infected with 20 MOI of Ad-hNIS were treated
with 0, 9.25, 18.5 and 37.0MBq of I-131 in HBSS or HBSS alone for
7h. Cellular viability assessed by the use of a clonogenic assay was
compared to treatment with I-131 or with HBSS alone (b). The data
shown are the means of experiments performed in triplicate. Bars
represent means±s.d.; NS, not significant; *statistically significant
Figure 3 Cellular cytotoxic effects of combined doxorubicin and
I-131 in both Ad-shMDR1 and Ad-hNIS-infected HCT15 cells. HCT-15
cells were infected with both Ad-shMDR1 (200 MOI) and Ad-hNIS
(20 MOI) for 48h. At 48h after viral infection, cells were treated with
HBSS, 9.25 and 18.5MBq of I-131 for 7h. I-131-treated cells (1000
cells per well) were incubated with or without 1 or 10mM doxorubicin
at 371C for 1 week. Cells were stained with a crystal violet solution
and colonies of more than 30 cells were counted. Results are
expressed as the percentage of surviving colonies. The data shown
are the means of experiments performed in triplicate. Bars represent
means±s.d.
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416±50 and 354±80%, respectively, Figure 6c).
Discussion
RNA interference (RNAi) has currently been used as a
valuable research tool to induce the suppression of
specific genes of interest using siRNA or micro RNA,
double-strand RNA molecules of short fragments of
19–25bp.
9 Several reports have shown the successful regu-
lation of the MDR1 gene and cancer treatment by the use
of RNA interference with in vivo models. Wu et al.
16 have
reported that small-interfering RNA-induced suppression
of MDR1 restores sensitivity to multidrug-resistant
human breast cancer cells by analysis of paclitaxel and
doxorubicin uptake in cancer cells and by the use of
methods such as RT-PCR analysis. Alexandra et al. have
also shown the stable and complete suppression of
MDR1/P-glycoprotein-mediated multidrug resistance in
human gastric or pancreatic carcinoma cell lines using
adenovirus expressing-MDR1 siRNA.
17 More recently,
Xueshi et al.
18 showed suppression of MDR1-mediated
multi-drug resistance using a lentivirus that expressed
MDR1 shRNA in human leukemia cells.
We have previously reported the additive therapeutic
effects of the combination of vector-based MDR1 RNA
Figure 4 In vivo imaging of tumor-bearing mice infected with both Ad-shMDR1 and Ad-hNIS. A total of 1 10
7 HCT-15 cells were s.c injected
into both thighs of mice. When the tumor volume reached approximately 100mm
3, Ad-shMDR1 (2 10
9PFU) and Ad-hNIS (1 10
9PFU) were
intratumorally injected into the tumor-bearing mice. Ad-LacZ as a control was intratumorally injected to tumor-bearing mice. At 2 days after virus
injection, gamma camera imaging was performed to detect Tc-99m sestamibi and Tc-99m pertechnetate (a and b). A fluorescence image was
obtained using the OPtix imaging system (c). Experiments were performed in triplicate; n¼5 mice/group.
Figure 5 Histopathological analysis of both Ad-shMDR1 and Ad-hNIS-infected tumors. Extracted tumors were fixed with 4% formalin overnight.
For immunohistological examination of Pgp and hNIS, paraffin sections (5mm thick) were incubated with anti-NIS (a, d) and anti-Pgp (b, e).
Ad-LacZ-infected tumors (control) were stained with X-gal stain solution (c) and were examined under a light microscope ( 200 magnification).
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Cancer Gene Therapyinterference and hNIS radioiodine gene therapy in human
colon cancer cells in vitro.
10 Although this new therapeutic
strategy was effective in vitro, some problems remain to be
solved for application in a clinical situation. Namely, a
stable transfectant expressing hNIS and MDR1 shRNA is
an artificial model to examine the therapeutic effects of
the combination of hNIS radioiodine gene therapy and
MDR1 shRNA therapy. Thus, new targeted methods
should be developed where MDR1 shRNA and the NIS
gene are only expressed in cancer models. Several
investigators have described tissue-specific delivery meth-
ods of therapeutic genes in various cancer models using
an adenoviral system.
19–22 These investigators have shown
that an adenovirus-mediated gene delivery system can
induce strong expression of therapeutic genes and
effective anti-tumor effects in some cancer models.
On the basis of these previous studies, we adopted the
use of an adenovirus-mediated delivery system for
effective expression of MDR1 shRNA and hNIS in a
human colon cancer model, a therapeutic strategy closer
to the clinical situation than that of the use of stable
transfectants as was reported previously. Although there
are some strategies for multiple therapeutic gene expres-
sion such as the use of a bicistronic vector (IRES) and
the fusion vector approach,
23 we constructed two types
of adenovirus expressing MDR1 shRNA or the human
NIS gene. An adenovirus mixture (Ad-shMDR1 and
Ad-hNIS) was used for in vitro and in vivo therapy
experiments. Previous studies have shown effective gene
expression of therapeutic genes and tumor growth
inhibition by co-injection of separate adenoviruses into
tumors.
24,25
By the use of Tc-99 sestamibi uptake analysis, we found
that an adenovirus-expressing MDR1 shRNA effectively
inhibited P-glycoprotein expression and caused an in-
crease in the uptake of Tc-99m sestamibi in infected
human colon cancer cells in vitro or in vivo (Figures 1a
and 4). Furthermore, we observed that Ad-hNIS infection
of cancer cells induced increased uptake of I-125 and
Tc-99m pertechnetate in infected human colon cancer cells in
in vitro and in vivo models (Figures 1a and 4). An in vitro
cellular cytotoxic assay showed increased cytotoxic effects
with the use of combination therapy (doxorubicin andþ
I-131) as compared with the use of single therapy either
with doxorubicin or I-131 (Figures 2 and 3). More
interestingly, the use of in vivo tumor therapy showed that
the adenovirus-mediated therapeutic strategies generated
significant inhibition of tumor growth for mice treated
with combination therapy, whereas slight tumor growth
inhibition effects were observed in mice treated with a
single therapy (Figure 6). The enhanced therapeutic
effects in vitro and in vivo can be explained based on the
following mechanisms. (1) Suppression of the MDR1 gene
and overexpression of NIS promoted the uptake of
radiotracers such as Tc-99m sestamibi, I-131 and
Tc-99m pertechnetate, (2) facilitated the accumulation
of a therapeutic drug such as doxorubicin and I-131 and
subsequently (3) induced strong tumor growth inhibition
in mice treated with combination therapy. Particularly,
hNIS radioiodine gene therapy could concentrate the beta
Figure 6 In vivo therapy of HCT15 colon tumor xenografts. Mice
were divided into four groups to assess combination therapy in vivo
when the diameters of tumors reached approximately 100mm
3 (’,
PBS; m, doxorubicin; E, I-131; K, doxorubicin plus I-131). A virus
mixture of Ad-shMDR1 (2 10
9PFU) and Ad-hNIS (1 10
9PFU)
was administered to mice by multiple injections of virus. Ad-LacZ as
a control was intratumorally injected to mice by multiple injections of
virus. At 2 days after virus injection, a single dose of I-131 (55.5MBq)
was injected and doxorubicin treatment (0.5mgkg
–1) was followed at
3-day intervals for 21 days (a). Tumor-bearing mice were injected
with either virus mixture (Ad-shMDR1 plus Ad-hNIS) (b) or Ad-LacZ
(c) followed by treatment with PBS, doxorubicin, I-131 or
doxorubicinþI-131. Tumor volume was measured using a caliper
over time. Experiments were performed in triplicate, n¼8 mice/
group. *statistically significant.
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Beta rays emitted from I-131 travel 0.2 to 2.4mm in
tissue,
26 which results in the death of cells near hNIS-
expressing cancer cells by cross-fire effects.
Although the anti-tumor effects and usefulness of
combination therapy was shown in the experiments, we
did not consider that the anti-tumor effects of combina-
tion therapy were related to adenovirus toxicity. Several
investigators have reported toxicity related to adenovirus
application to living organisms. For example, toxicity
such as an increase of aspartate aminotransferase and
alanine aminotransferase levels and low stability of the
system are suggested as risk factors for the therapeutic use
of an adenoviral vector delivery system. However,
continued trials for viruses packaged into HEK 293 cells
or local application of small particles into limited areas, as
was performed in our study, have successfully reduced the
risks of infection and other definitive risk factors.
11,12 As
described above, a further study should be performed to
investigate the safety of combination therapy of MDR1
shRNA therapy and hNIS radioiodine gene therapy using
the adenoviral system.
In conclusion, combined Ad-shMDR1 gene therapy
and hNIS radioiodine gene therapy (1) enhanced the
uptake of Tc-99m sestamibi and Tc-99m pertechnate
in vitro and in vivo, (2) increased the cellular cytotoxic
effects of doxorubicin and I-131 in vitro and (3) generated
stronger anti-tumor effects in a mouse colon cancer
model. Combination therapy strategies using an adeno-
virus-mediated method may have clinical potential in
cancer patients who are non-responsive to conventional
chemotherapy.
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